ERAS Erasca, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1761918 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-141.2%
TTM EPS YoY-125.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-48.7%
ROA-43.4%
ROIC (approx.)-48.1%
Asset turnover—
Leverage & solvency
Liabilities / assets8.2%
Debt / equity0.00x
Current ratio14.89x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.35x
Accruals ratio-28.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $92.85M | $115.36M | $103.82M | $112.46M | $73.92M |
| SG&A expense | $38.55M | $41.73M | $37.70M | $32.99M | $22.62M |
| Operating income | -$140.91M | -$179.59M | -$141.53M | -$247.45M | -$124.88M |
| Pretax income | -$124.55M | -$161.65M | — | — | — |
| Income tax | $0 | $0 | — | — | — |
| Net income | -$124.55M | -$161.65M | -$125.04M | -$242.81M | -$122.76M |
| EBITDA | -$137.80M | -$175.78M | -$137.79M | -$244.81M | -$124.05M |
| EPS (basic) | -0.44 | -0.69 | -0.83 | -1.99 | -1.85 |
| EPS (diluted) | -0.44 | -0.69 | -0.83 | -1.99 | -1.85 |
| Dividends declared per share | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Weighted avg. shares (diluted) | 283.53M | 233.82M | 150.18M | 122.02M | 66.29M |
| Balance sheet | |||||
| Cash & equivalents | $73.81M | $67.74M | $93.08M | $284.22M | $360.49M |
| Short-term investments | $202.27M | $230.57M | $219.28M | $151.40M | $53.99M |
| Current assets | $286.24M | $308.79M | $320.68M | $444.50M | $420.02M |
| PP&E, net | $13.30M | $16.32M | $22.33M | $24.82M | $15.95M |
| Total assets | $396.15M | $502.53M | $395.30M | $514.91M | $501.42M |
| Current liabilities | $28.51M | $31.39M | $26.16M | $48.69M | $26.22M |
| Total liabilities | $70.98M | $79.03M | $78.61M | $103.06M | $44.89M |
| Shareholders' equity | $325.17M | $423.50M | $316.69M | $411.85M | $456.53M |
| Shares outstanding | 284.16M | 283.22M | 151.09M | 149.33M | 119.10M |
| Cash flow statement | |||||
| Operating cash flow | -$95.45M | -$109.42M | -$101.22M | -$103.26M | -$79.60M |
| Capital expenditure | $128,000 | $60,000 | $1.77M | $14.55M | $11.21M |
| Free cash flow | -$95.58M | -$109.48M | -$102.99M | -$117.81M | -$90.81M |
| Investing cash flow | $100.42M | -$156.62M | -$91.22M | -$71.08M | -$64.59M |
| Financing cash flow | $1.10M | $240.70M | $1.29M | $98.08M | $439.40M |
| Depreciation & amortization | $3.11M | $3.81M | $3.73M | $2.64M | $829,000 |
| Stock-based compensation | $24.90M | $26.97M | $26.23M | $20.11M | $8.33M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.